Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis (VAXAK)
Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis - a Double-blind Randomized Controlled Trial
Sponsor: Merete Haedersdal
Listed as NCT05202860, this PHASE2 trial focuses on Actinic Keratoses and Basal Cell Carcinoma and remains ongoing. Sponsored by Merete Haedersdal, it has been updated 12 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Feb 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Dec 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Aug 2023 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merete Haedersdal
For direct contact, visit the study record on ClinicalTrials.gov .